Abstract

Prestige Consumer Healthcare will release fiscal fourth-quarter results on May 13, 2026 Post Market; this preview outlines consensus revenue, profit trajectory, and EPS forecasts, assesses margin drivers and the incremental implications of the announced Breathe Right acquisition, and distills prevailing analyst views ahead of the print.

Market Forecast

Consensus for the quarter to be reported points to revenue of 294.73 million US dollars, up 1.86% year over year, adjusted EPS of 1.39, up 7.04% year over year, and EBIT of 98.25 million US dollars, up 2.49% year over year. The company has not guided a gross margin or net margin for the quarter in the dataset, but consensus implies modest top-line growth and incremental EPS leverage versus last year’s comparable period.

Within the franchise, Gastrointestinal and Women’s Health are expected to anchor the revenue base, building from last quarter’s category contributions and supported by steady shelf placement and marketing cadence. Respiratory care has the most visible near-term growth potential, with last quarter’s cough and cold category at 29.33 million US dollars and the announced addition of Breathe Right introducing a new growth vector; while segment-specific year-over-year growth was not disclosed in the segmentation, company-wide revenue is forecast to grow 1.86% year over year this quarter.

Last Quarter Review

Prestige Consumer Healthcare reported revenue of 283.44 million US dollars last quarter, with a gross profit margin of 56.38%, GAAP net profit attributable to shareholders of 46.70 million US dollars, a net margin of 16.47%, and adjusted EPS of 1.14; versus the prior year, revenue declined 2.37% and adjusted EPS declined 6.56%.

Sequentially, net profit improved by about 10.63%, reflecting stable gross margin and disciplined operating spending. By category, Gastrointestinal generated 69.45 million US dollars, Women’s Health 57.77 million US dollars, Eye and Ear Care 38.60 million US dollars, Dermatology 29.64 million US dollars, Cough and Cold 29.33 million US dollars, Analgesics 28.03 million US dollars, Oral Care 26.58 million US dollars, and Other OTC 4.04 million US dollars, indicating a diversified top line with multiple brand pillars; year-over-year growth by category was not disclosed in the segmentation data.

Current Quarter Outlook

Main business: Gastrointestinal and Women’s Health

Gastrointestinal and Women’s Health remain the core revenue engines, providing scale, broad household penetration, and high brand awareness across major retail partners. Coming off last quarter’s 69.45 million US dollars in Gastrointestinal and 57.77 million US dollars in Women’s Health, this quarter’s baseline should reflect normal seasonal demand with incremental lifts from in-store promotions and digital activation that typically cluster around spring shelf resets. With company-wide revenue expected to grow 1.86% year over year, these categories are positioned to provide the majority of the absolute dollar growth given their size.

From a margin lens, these categories typically carry healthy gross profit given brand equity and pricing power in nonprescription staples, and the prior-quarter gross margin of 56.38% provides a reasonable starting point. Mix within Gastrointestinal (for example, travel-driven motion-sickness SKUs in peak travel corridors) and within Women’s Health (such as higher-margin treatment SKUs versus prevention) can create modest gross margin variability quarter to quarter. Promotional cadence will matter: if retailers deploy broader buy-one-get-one and feature ads to drive footfall, gross margin could see mild pressure, but management’s past discipline suggests promotional spending is targeted and ROI-driven, which supports stability. We also note that unit elasticity has historically been manageable following measured list-price actions, which supports the forecast of higher EPS growth than revenue growth this quarter.

On operating expenses, advertising and consumer promotion dollars are likely to remain concentrated behind large, durable brands in these two categories. The consensus path to 1.39 EPS this quarter assumes Prestige continues to leverage SG&A—i.e., growing below sales—helped by ongoing digital media efficiency and better creative rotation. Assuming similar effective tax and modest interest expense changes, the conversion of incremental revenue to EPS should be stronger than in the same quarter last year, consistent with the forecast for 7.04% EPS growth.

Most promising business: Respiratory care, catalyzed by the Breathe Right acquisition

The cough and cold category posted 29.33 million US dollars last quarter and is poised for a structurally larger opportunity with the announced acquisition of the Breathe Right nasal strips brand. Breathe Right extends Prestige’s presence in everyday respiratory wellness with a product that benefits from repeat purchase behavior, high name recognition, and broad shelf presence adjacent to sinus, allergy, and sleep aids. While initial consolidation timing relative to the fiscal fourth quarter will dictate how much of Breathe Right is reflected immediately, the strategic implication is clear: an expanded respiratory platform that can benefit from Prestige’s commercial engine and retailer relationships.

The financial contours are supportive. Analyst commentary within the period indicates expectations for accretion, which implies that Breathe Right’s margin structure is at least in line with the corporate average and that fixed-cost absorption and brand support can be managed within existing infrastructure. This should enhance the respiratory category’s contribution over the next four quarters and provide cross-merchandising opportunities—such as co-features with decongestants or sleep-related SKUs—improving turns and shelf productivity. If integration proceeds smoothly, Prestige can unlock purchasing efficiencies in materials and packaging, reduce duplicate overhead, and channel trade investments more effectively, which together should support EBIT growth consistent with or better than the forecasted 2.49% company-wide year-over-year increase for this quarter.

Seasonality is a nuance. Cough and cold is inherently seasonal, and the March quarter can be a shoulder period as cold-season wanes. However, Breathe Right also connects to allergy and sleep quality use cases, smoothing seasonality to an extent. That broader usage, along with incremental distribution gains and refreshed creative, could extend category momentum into nonpeak months. As Prestige layers Breathe Right into its e-commerce and retail promotion calendar, expect to see faster test-and-learn cycles driving improved media ROAS and higher digital conversion, especially in search and auto-replenishment channels.

Key stock-price swing factors this quarter

Margin trajectory and operating leverage will be a primary swing factor. Last quarter’s gross margin of 56.38% sets a solid base, but investors will look for confirmation that freight normalization, procurement discipline, and controlled promotions preserve or improve this level. With revenue growth forecast at 1.86% and EPS growth at 7.04%, incremental evidence of SG&A leverage—without starving brand support—would align with consensus. Any variance in gross margin of ±50 basis points can have an outsized effect on EBIT, given the revenue scale, so commentary around input costs and promotional intensity will matter for the print and the stock’s reaction.

Integration color and timeline for Breathe Right will also influence sentiment. Clarity on expected closing, initial consolidation timing, integration costs, and the expected run-rate of revenue and EPS accretion will shape multi-quarter modeling. Investors will parse whether accretion arrives in the first full quarter post-close, how quickly procurement and overhead synergies can be captured, and whether there is a stepped-up advertising plan to re-energize household penetration. Because consensus already embeds moderate EPS growth, upside from earlier or larger-than-expected accretion could be a meaningful positive catalyst.

Retailer inventory and the promotional environment remain relevant. The prior year saw pockets of volatility in sell-in versus sell-through as retailers adjusted on-hand inventory. Evidence that inventories are normalized—and that sell-through aligns with shipment trends—reduces the risk of shipment pauses. Management’s comments on order patterns into the early weeks of the June quarter will be read as a signal for fiscal 2027. If feature and display support returns to pre-disruption levels without requiring higher trade spend, it would support the forecast EPS growth profile and may allow Prestige to flex advertising investment toward launches and re-supports with better-than-average returns.

The P&L below-the-line items bear monitoring. Interest expense can fluctuate with acquisition financing and debt structure; if Breathe Right is financed with incremental borrowing, the impact on quarterly interest should be sized. That said, consensus modeling for a 98.25 million US dollars EBIT suggests investors expect net financing costs to remain manageable relative to operating gains. Tax rate assumption stability matters for EPS conversion as well. Capital allocation—namely, the cadence of share repurchases—can also provide a small EPS tailwind if executed within existing authorization during periods of share price weakness.

Finally, guidance and qualitative commentary will be crucial for the forward path. Prestige’s outlook on organic revenue growth, A&P as a percentage of sales, and the timing of integration benefits from Breathe Right will frame fiscal 2027 expectations. Any incremental disclosure on product innovation, packaging refreshes, and distribution gains—particularly in the respiratory and women’s health platforms—will help investors refine growth and margin assumptions beyond the current quarter’s 1.86% revenue growth and 7.04% EPS increase baseline.

Analyst Opinions

The majority of analyst commentary in the covered period is bullish, with supportive views emphasizing the strategic and financial merits of adding Breathe Right and the resilience of the branded OTC portfolio. A noted example is Canaccord Genuity, which reiterated a Buy rating and an 86 US dollars target in March, citing the prospective accretion and strategic fit from the Breathe Right acquisition. William Blair also maintained a Buy stance in March, framing the deal as a sensible expansion at an attractive valuation that should strengthen the respiratory wellness platform and provide incremental growth levers.

The bullish cohort’s core arguments converge on three points. First, the acquisition deepens Prestige’s presence in an adjacent, high-awareness consumer need-state, enabling efficient cross-promotion and incremental shelf space without diluting brand equity elsewhere in the portfolio. This supports a faster ramp in revenue than an organic launch would, with lower execution risk given the brand’s established demand. Second, accretive financials—implied by multiple buy-side and sell-side references—suggest that gross margin and operating margin will either match or exceed corporate averages, providing a mechanism for EPS growth to outperform revenue growth, consistent with this quarter’s expectation of 7.04% EPS growth on 1.86% revenue growth. Third, Prestige’s operating playbook—focused A&P, disciplined trade spend, procurement synergies, and efficient SG&A—has historically allowed it to absorb acquired assets while preserving or enhancing margin structure, which the bullish camp expects to repeat.

From a near-term perspective, bullish analysts view this quarter’s setup as balanced to positive. With consensus revenue at 294.73 million US dollars and EBIT at 98.25 million US dollars, the hurdle is not onerous if gross margin remains near last quarter’s 56.38% and SG&A trends modestly below sales growth. Upside could stem from better-than-expected sell-through in core categories, early integration traction, or a lighter trade-spend environment if retailer promotions maintain efficiency without requiring incremental funding. The primary watch items remain confirmation of consolidation timing for Breathe Right and any commentary on second-half pacing that would affect full-year growth assumptions.

In synthesizing these perspectives, the bullish majority expects Prestige Consumer Healthcare to deliver a quarter that confirms stability in core categories, demonstrates operating discipline consistent with the 2.49% year-over-year EBIT growth forecast, and articulates a credible plan to unlock value from Breathe Right. The anticipated combination of steady top line, controlled expenses, and incremental accretion potential underpins the constructive stance into the print, with attention trained on qualitative disclosures that could lift outer-quarter expectations if execution aligns with the company’s established track record.